Zócalo Health | $15,000,000 | (Apr 24, 2026)
Rilian | $17,500,000 | (Apr 24, 2026)
BAND | $17,000,000 | (Apr 24, 2026)
Certified by Founder
Lodge
Congruence Therapeutics
start up
Canada
- Montreal, Quebec
- 07/03/2023
- Series A
- $65,000,000
Congruence Therapeutics is a drug discovery company that is uniquely harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning and computational chemistry. Our ground-breaking discovery engine, Revenir, sees proteins in ways others have been unable to see - in their full dynamic state.
- Industry Biotechnology Research
- Website https://congruencetx.com/
- LinkedIn https://www.linkedin.com/company/congruencetx/people/
Related People
Clarissa DesjardinsFounder
Canada -
Montreal, Quebec,
Experienced biotechnology executive and founder of three successful biotechnology companies. Founded Clementia Pharmaceuticals and led it to Phase 3 human clinical trials for fibrodysplasia ossificans progressiva (FOP), a disease of abnormal new bone formation, until its acquisition by Ipsen for $1.3 billion dollars in 2019.
Brev.io | $3,300,000 | (Apr 24, 2026)
Maxed | $850,000 | (Apr 24, 2026)
Omni | $120,000,000 | (Apr 24, 2026)
VREY | $3,859,432 | (Apr 24, 2026)
Astor (YC S25) | $5,000,000 | (Apr 24, 2026)
QMatter | $1,200,000 | (Apr 24, 2026)
Almanac Health | $10,000,000 | (Apr 24, 2026)
Petual | $20,000,000 | (Apr 24, 2026)
C-Infinity | $16,000,000 | (Apr 23, 2026)